Universal anti-cd22 chimeric antigen receptor engineered immune cells
AssigneeCellectis
InventorsJulianne SMITH, Phillippe DUCHATEAU, Murielle DERRIEN
Life of this patent
Estimating the term…
Abstract
The present invention relates to an engineered immune cell endowed with a new CD22 Chimeric Antigen Receptors (CD22 CAR) with a deletion in the TRAC gene that is able to redirect said immune cell specificity and reactivity toward selected tumor cells. The engineered immune cells endowed with such CARs are particularly suited for treating relapsed refractory CD22 expressing cancers.
Claims21
1-27. (canceled)
A method of preparing T cells for immunotherapy comprising introducing ex-vivo into human T cells a polynucleotide encoding a Chimeric Antigen Receptor specific for CD22 (anti-CD22 CAR) comprising the amino acid sequence of SEQ ID NO:
- 15.
Dependencies are inferred from the claim text.